Paul Argenti, Dartmouth Tuck School of Business professor, joins 'Squawk Box' to discuss news of activist investor Starboard Value amassing a roughly $1 billion stake in drugmaker Pfizer, whether Pfizer makes sense as an activist target, and more.
Pfizer Inc. PFE may have been a hero in the COVID-19 vaccine race, but its stock is stuck in the slow lane. Down nearly 14% over the last year, the pharma giant's shares have struggled as demand for its pandemic-related treatments has fizzled out.
Shares of Pfizer (PFE) are rising in premarket trading Monday following a report that activist investor Starboard Value has taken a roughly $1 billion stake in the struggling drugmaker.
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine.
Activist investor Starboard Value is seeking to spur a turnaround of Pfizer, taking a stake of about $1 billion in the struggling pharmaceuticals giant, according to a person familiar with the matter. Charlie Wells reports on Bloomberg Television.
Activist investor Starboard Value has reportedly amassed a $1 billion stake in Pfizer.
In a bid to reshape Pfizer's future, activist investor Starboard Value has acquired a stake worth approximately $1 billion, according to reports. The move comes as the pharmaceutical giant faces mounting challenges, including declining demand for its Covid-19 products and increased competition.
Activist investor Starboard Value has acquired a $1 billion stake in Pfizer Inc (NYSE:PFE, ETR:PFE) and is pushing for changes at the pharmaceutical giant, according to the Wall Street Journal. While Starboard's specific plans remain unclear, it has reportedly engaged with former Pfizer executives Ian Read and Frank D'Amelio to support its efforts.
Activist investor Starboard Value has taken a $1 billion stake in beleaguered drugmaker Pfizer Inc. and is seeking a turnaround, the Wall Street Journal reported late Sunday.
Starboard Value has taken a significant stake in Pfizer, said people familiar with the matter. The drug giant's stock has dropped significantly since its 2021 COVID-19 vaccine rollout.
Starboard Value has amassed a roughly $1 billion stake in drugmaker Pfizer, according to people familiar with the matter. The activist fund run by Jeff Smith is looking to tap former Pfizer CEO Ian Read and ex-finance chief Frank D'Amelio, although it is unclear in what capacity.
The drugmaker's shares have slumped as demand for Covid-19 vaccines and treatments has slowed.